Millennium, Ferring Sign Marketing and Distribution Pact

Millennium Biotechnologies, Inc. has entered into a five-year exclusive distribution agreement for Resurgex, its nutritional formula for immuno-comprised patients, with Ferring, Inc. of Canada, a division of Ferring S.A. 

Under the agreement, Ferring will have the exclusive right to use the Resurgex trademarks and sell the Resurgex line of products in Canada. Ferring will be responsible for the marketing, distribution and sales efforts throughout Canada. Ferring will also purchase all products from Millennium Biotechnologies and will promote Resurgex to various specialist groups throughout Canada.

Richard Jeysman, president of Ferring stated, “Resurgex’s proven success in the unequivocally demonstrates this product’s ability to help immuno-compromised patients better deal with various disorders such as cancer, and afflictions of the gastrointestinal tract.”

“Given the exhaustive evaluation, which they have conducted, and the size of their investment, this is a significant step for Millennium Biotechnologies in the international commercialization of our product line” stated Mark C. Mirken, president and chief operating officer of Millennium Biotechnology.